Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Heartseed Inc. is a Japan-based company engaged in research and development of regenerative medicine products. The company has established cardiac regenerative medicine, a therapy in which microtissue derived from iPS cells is transplanted into the heart for patients with severe heart failure. Target diseases include dilated cardiomyopathy, old myocardial infarction, and dilated-phase hypertrophic cardiomyopathy.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overpriced on P/FCF.
Target Price
The average target price of 219A.T is 4000 and suggests 48% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr